Developer docs
API playgroundTry for free, no card

Search company profiles

Roukenbio

Full company profile

uuid00bzz2e

Namestring
Roukenbio
Legal namestring
RoukenBio Ltd
Websiteurl
rouken.bio
Company typeenum
Private
Founded yearint
2015
Descriptiontext

RoukenBio is a preclinical contract research organisation (CRO) specialising in immunology, founded in 2015 in Scotland (formerly as Antibody Analytics). The company provides fee-for-service drug development support to global biotechnology and pharmaceutical companies from early discovery through pre-IND testing, covering small molecule, large molecule, and advanced therapeutics including antibodies, cell therapies, and biosimilars. Its service portfolio spans immune cell assays (dendritic cells, T cells, NK cells, B cells, neutrophils, macrophages, tumour cells, granulocytes, and whole blood), biosimilar characterisation, immunotoxicology, and therapeutic-area-focused programmes in allergy and autoimmunity.

The company's technical differentiation rests on two proprietary cell-engineering platforms: IndEx-2, a dual inducible cell line system that enables independent titratable expression of target antigens for evaluating antigen density activation thresholds in CAR-T, bispecific antibodies, ADCs, and immune cell engagers; and LocIn, a Recombinase Mediated Cassette Exchange-based targeted integration system that generates isogenic mammalian cell lines and reduces cell line development timelines by approximately six weeks. A separate sub-brand, RoukenCells, distributes off-the-shelf IndEx-2 cell lines, reporter cell lines, and immune cell banks. Multiple patents are filed in cell line engineering and CAR-T cell therapy (co-inventor Dr Timothy London, ex-MedImmune and ex-TC BioPharm).

RoukenBio operates from a 2,000 m² Discovery Centre in Motherwell, Scotland, with 484 m² of laboratory space. It employs 100+ staff, serves customers in 25 countries, and reports an NPS of 79 with customer satisfaction scores above 9/10 across knowledge, timelines, communication, and overall satisfaction. Revenue is generated through bespoke, quote-based project contracts, with a consultative enterprise sales motion routed through HubSpot meeting scheduling. The company received growth investment from NorthEdge in 2023 and announced a strategic partnership with AVS Bio in February 2026 to integrate antibody discovery with mechanism-driven functional characterisation.

Short descriptiontext

RoukenBio is a preclinical immunology CRO providing cell-based assay services, custom cell line engineering, and biosimilar characterisation to global biotechnology and pharmaceutical companies from early discovery through pre-IND testing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMotherwell, United Kingdom
HQ citystring
Motherwell
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical immunology CRO, immune cell assays, custom cell line engineering, biosimilar characterisation services, drug discovery CRO
Industry4 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code4 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Preclinical Immunology Contract Research Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

RoukenBio operates as a preclinical Contract Research Organisation (CRO) providing immunology-focused drug development services. Services span from early discovery through pre-IND testing, supporting small molecule, large molecule, and advanced therapy development. Revenue is generated through fee-for-service research contracts with biotechnology and pharmaceutical companies.

rouken.bio
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

RoukenBio is a preclinical immunology Contract Research Organisation (CRO) providing bespoke drug discovery and development services from early discovery through pre-IND testing. Its core offering covers immune cell-based assays, custom cell line engineering, biosimilar characterisation, immunotoxicology, and therapeutic area expertise in allergy and autoimmunity, supported by proprietary IndEx-2 and LocIn platforms. The RoukenCells sub-brand additionally supplies off-the-shelf engineered cell lines, reporter cells, and immune cell banks for client in-house workflows.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Net Promoter Score of 79, indicating exceptionally high customer satisfaction and loyalty
+2 more records
Product overview1 text field

RoukenBio is a preclinical immunology CRO providing discovery to IND-enabling research services as a unified offering across the drug development lifecycle. The core portfolio spans immune cell assays (covering dendritic cells, T cells, NK cells, B cells, neutrophils, macrophages, tumour cells, granulocytes, and whole blood), custom cell line engineering (built on proprietary IndEx-2 and LocIn platforms), biosimilars testing, immunotoxicology, and therapeutic focus areas in allergy and autoimmunity. RoukenCells operates as a separate sub-brand providing off-the-shelf cell products including IndEx-2 cell lines, reporter cells, and immune cell banks.

Product and service10 records
1Preclinical Immunology CRO Services
CategoryContract Research Services
Description

Preclinical contract research organisation services covering the full spectrum of discovery to pre-IND testing, supporting small molecule, large molecule, and advanced therapeutics development from early discovery through clinical phases for biotechnology and pharmaceutical clients globally.

2Immune Cell Assays
CategoryImmunology Assay Services
Description

In vitro immunology assay services covering dendritic cell assays, T cell assays, NK cell assays, B cell assays, neutrophil assays, macrophage assays, tumour cell assays, granulocyte assays, and whole blood assays for drug discovery and preclinical development.

3IndEx-2 Dual Inducible Cell Line Platform
CategoryProprietary Technology Platform / Cell Line Engineering
Description

Proprietary dual inducible cell line platform that independently modulates expression of one or two target antigens across biologically relevant densities, enabling determination of antigen density activation thresholds for targeted immunotherapies including CAR-T cells, bispecific antibodies, ADCs, and immune cell engagers.

4LocIn Targeted Integration System
CategoryProprietary Technology Platform / Cell Line Engineering
Description

Advanced targeted integration system for efficient generation of genetically identical isogenic mammalian cell lines using Recombinase Mediated Cassette Exchange (RMCE), removing the need for subcloning and reducing cell line generation timeline by approximately 6 weeks.

5Custom Cell Line Engineering
CategoryCell Line Engineering Services
Description

Bespoke cell line development services including gene editing, reporter cell lines, target-expressing cell lines, defined expression levels, and CAR-T cells engineered to meet specific therapeutic modality requirements.

6Biosimilar Characterisation and Testing Services
CategoryBiosimilar Development Services
Description

Comprehensive biosimilar characterisation services including analytical similarity strategy, MOA-reflective binding and functional assays, Fab/Fc binding assessments, ADCC/CDC assays, and regulatory-compliant comparative data generation for biosimilar developers.

7Immunotoxicology Assays
CategoryImmunotoxicology Services
Description

In vitro immunotoxicology services including PBMC cytokine release assays, on-target off-tumour side effect prediction using IndEx-2, and immunogenicity assessments (DC maturation, T cell activation, ADA assay development) for early immune safety assessment.

8Allergy Therapeutic Development Services
CategoryTherapeutic Area Services - Allergy
Description

Advanced human in vitro allergy assay platforms modelling core type 2 inflammatory pathways including IgE/FcεRI signalling, mast cell and basophil activation, eosinophil function, Th2 cytokine biology, and B-cell class switching for biologics and small molecule therapeutics.

9Autoimmune Assays and Drug Discovery Services
CategoryTherapeutic Area Services - Autoimmunity
Description

Human-relevant in vitro autoimmune assays including mixed lymphocyte reactions, T cell activation/suppression/polarisation assays, Treg suppression assays, macrophage polarisation assays, B cell depletion assays, and T cell depletion assays for immunotherapy evaluation.

10RoukenCells Cell Product Line
CategoryCell Product Sub-Brand
Description

Cell product arm of RoukenBio providing off-the-shelf engineered cell lines including IndEx-2 cell lines, reporter cell lines, and standardised/bespoke primary human immune cell banks for seamless integration into customers' internal assay workflows.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-17
Description

Strategic partnership to integrate antibody discovery and development services with mechanism-driven functional characterisation. Combines AVS Bio's design-focused discovery platforms with RoukenBio's cell-based and primary immune cell assay systems. Creates an end-to-end antibody engine to improve lead candidate prioritisation and reduce translational uncertainty before IND-enabling studies. AVS Bio has supported over 100 life sciences companies since 2018, with 10 antibodies entering clinical trials.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

GLP & GCP compliant CRO specialising in advanced tissue-based biomarker analysis including histology, immunohistochemistry (IHC), immunofluorescence (IF), in situ hybridisation (ISH), and digital image analysis services for therapeutic and medical device development.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Leading product development and regulatory consulting practice serving pharmaceutical and biotechnology industry. Offers strategic and operational support in quality/CMC, non-clinical/toxicology, clinical/medical and regulatory affairs. Team members based in UK, Ireland, Netherlands and US.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Established global antibody expression service provider located in Zurich, Switzerland. Specialised in CHO-based transient expression of antibodies including bispecific and fusion antibodies. Track record of more than 125,000 transfections performed and more than 20,000 antibodies expressed and purified.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Developer of best-in-class lab-on-chip screening platforms for 3D disease models. Offers patented technology providing higher throughput investigation of candidate molecules on translational live tissue samples and complex 3D models. Delivers over 20 times more data than existing methods.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Discovery and preclinical CRO providing immunology, cell-based assay and biosimilar services; competes in adjacent preclinical spaces with mid-tier scale similar to RoukenBio.

TypeBroad incumbent
Description

Large global CRO network with immunology and cell-based assay capabilities as part of a broad discovery services portfolio; competes with RoukenBio on immunology projects but as one of many service lines.

TypeEmerging player
Description

Smaller specialty CRO offering primary immune cell isolation, cell-based assays and immunology services to biopharma - emerging niche player with similar but more limited offering than RoukenBio.

TypeBroad incumbent
Description

Large CRO offering immunology, cell-based assay and biosimilar characterization services across the full drug development lifecycle - significant overlap with RoukenBio's preclinical offerings, especially in biosimilars.

TypeBroad incumbent
Description

Global CRO/CDMO with cell biology, immunology and biosimilar capabilities; competes with RoukenBio on preclinical immunology projects, with broader integrated discovery-to-manufacturing offering.

TypeDirect peer
Description

Specialty immunology services CRO offering cell-based assays, MHC-peptide binding, and immune monitoring services to biopharma - directly comparable niche specialization and customer base to RoukenBio.

TypeBroad incumbent
Description

Major global CRO offering immunology, cell-based assays and biosimilar services as part of an end-to-end discovery and development portfolio - broader scope and scale but overlapping capabilities.

8Caprion Biosciences (CellCarta)
TypeDirect peer
Description

Immunology and biomarker CRO with strong flow cytometry, immunophenotyping and cell-based assay capabilities serving biopharma; operates at a slightly larger scale but with similar specialty positioning.

TypeDirect peer
Description

Specialty CRO focused on hematology and immunology cell-based assays, including primary human cell assays - direct niche competitor in similar cell-based immunology services.

TypeDirect peer
Description

Immunology-focused CRO specializing in immune cell assays, antibody characterization and immunogenicity testing using primary human immune cells - closely overlaps RoukenBio's core preclinical immunology service offering.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights1 record

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Roukenbio

Preclinical Immunology Contract Research Servicesrouken.bio

RoukenBio is a preclinical immunology CRO providing cell-based assay services, custom cell line engineering, and biosimilar characterisation to global biotechnology and pharmaceutical companies from early discovery through pre-IND testing.

What Roukenbio does

RoukenBio is a preclinical contract research organisation (CRO) specialising in immunology, founded in 2015 in Scotland (formerly as Antibody Analytics). The company provides fee-for-service drug development support to global biotechnology and pharmaceutical companies from early discovery through pre-IND testing, covering small molecule, large molecule, and advanced therapeutics including antibodies, cell therapies, and biosimilars. Its service portfolio spans immune cell assays (dendritic cells, T cells, NK cells, B cells, neutrophils, macrophages, tumour cells, granulocytes, and whole blood), biosimilar characterisation, immunotoxicology, and therapeutic-area-focused programmes in allergy and autoimmunity.

The company's technical differentiation rests on two proprietary cell-engineering platforms: IndEx-2, a dual inducible cell line system that enables independent titratable expression of target antigens for evaluating antigen density activation thresholds in CAR-T, bispecific antibodies, ADCs, and immune cell engagers; and LocIn, a Recombinase Mediated Cassette Exchange-based targeted integration system that generates isogenic mammalian cell lines and reduces cell line development timelines by approximately six weeks. A separate sub-brand, RoukenCells, distributes off-the-shelf IndEx-2 cell lines, reporter cell lines, and immune cell banks. Multiple patents are filed in cell line engineering and CAR-T cell therapy (co-inventor Dr Timothy London, ex-MedImmune and ex-TC BioPharm).

RoukenBio operates from a 2,000 m² Discovery Centre in Motherwell, Scotland, with 484 m² of laboratory space. It employs 100+ staff, serves customers in 25 countries, and reports an NPS of 79 with customer satisfaction scores above 9/10 across knowledge, timelines, communication, and overall satisfaction. Revenue is generated through bespoke, quote-based project contracts, with a consultative enterprise sales motion routed through HubSpot meeting scheduling. The company received growth investment from NorthEdge in 2023 and announced a strategic partnership with AVS Bio in February 2026 to integrate antibody discovery with mechanism-driven functional characterisation.

Roukenbio firmographics

Firmographics
Name
Roukenbio
Legal name
RoukenBio Ltd
Website
https://rouken.bio
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
RoukenBio is a preclinical immunology CRO providing cell-based assay services, custom cell line engineering, and biosimilar characterisation to global biotechnology and pharmaceutical companies from early discovery through pre-IND testing.
Ownership category
akta.pro rank

Roukenbio industry classification

Industry
Product category
Preclinical Immunology Contract Research Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • Preclinical immunology CRO
  • Immune cell assays
  • Custom cell line engineering
  • Biosimilar characterisation services
  • Drug discovery CRO

Where Roukenbio is headquartered

Location

Headquarters

HQ city
Motherwell
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Roukenbio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services: RoukenBio operates as a preclinical Contract Research Organisation (CRO) providing immunology-focused drug development services. Services span from early discovery through pre-IND testing, supporting small molecule, large molecule, and advanced therapy development. Revenue is generated through fee-for-service research contracts with biotechnology and pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Roukenbio product offering

Product offering

Core offering

RoukenBio is a preclinical immunology Contract Research Organisation (CRO) providing bespoke drug discovery and development services from early discovery through pre-IND testing. Its core offering covers immune cell-based assays, custom cell line engineering, biosimilar characterisation, immunotoxicology, and therapeutic area expertise in allergy and autoimmunity, supported by proprietary IndEx-2 and LocIn platforms. The RoukenCells sub-brand additionally supplies off-the-shelf engineered cell lines, reporter cells, and immune cell banks for client in-house workflows.

Product overview

RoukenBio is a preclinical immunology CRO providing discovery to IND-enabling research services as a unified offering across the drug development lifecycle. The core portfolio spans immune cell assays (covering dendritic cells, T cells, NK cells, B cells, neutrophils, macrophages, tumour cells, granulocytes, and whole blood), custom cell line engineering (built on proprietary IndEx-2 and LocIn platforms), biosimilars testing, immunotoxicology, and therapeutic focus areas in allergy and autoimmunity. RoukenCells operates as a separate sub-brand providing off-the-shelf cell products including IndEx-2 cell lines, reporter cells, and immune cell banks.

Differentiator

Problem solved

Functional benefit

Products and services

  • Preclinical Immunology CRO Services Preclinical contract research organisation services covering the full spectrum of discovery to pre-IND testing, supporting small molecule, large molecule, and advanced therapeutics development from early discovery through clinical phases for biotechnology and pharmaceutical clients globally.
  • Immune Cell Assays In vitro immunology assay services covering dendritic cell assays, T cell assays, NK cell assays, B cell assays, neutrophil assays, macrophage assays, tumour cell assays, granulocyte assays, and whole blood assays for drug discovery and preclinical development.
  • IndEx-2 Dual Inducible Cell Line Platform Proprietary dual inducible cell line platform that independently modulates expression of one or two target antigens across biologically relevant densities, enabling determination of antigen density activation thresholds for targeted immunotherapies including CAR-T cells, bispecific antibodies, ADCs, and immune cell engagers.
  • LocIn Targeted Integration System Advanced targeted integration system for efficient generation of genetically identical isogenic mammalian cell lines using Recombinase Mediated Cassette Exchange (RMCE), removing the need for subcloning and reducing cell line generation timeline by approximately 6 weeks.
  • Custom Cell Line Engineering Bespoke cell line development services including gene editing, reporter cell lines, target-expressing cell lines, defined expression levels, and CAR-T cells engineered to meet specific therapeutic modality requirements.
  • Biosimilar Characterisation and Testing Services Comprehensive biosimilar characterisation services including analytical similarity strategy, MOA-reflective binding and functional assays, Fab/Fc binding assessments, ADCC/CDC assays, and regulatory-compliant comparative data generation for biosimilar developers.
  • Immunotoxicology Assays In vitro immunotoxicology services including PBMC cytokine release assays, on-target off-tumour side effect prediction using IndEx-2, and immunogenicity assessments (DC maturation, T cell activation, ADA assay development) for early immune safety assessment.
  • Allergy Therapeutic Development Services Advanced human in vitro allergy assay platforms modelling core type 2 inflammatory pathways including IgE/FcεRI signalling, mast cell and basophil activation, eosinophil function, Th2 cytokine biology, and B-cell class switching for biologics and small molecule therapeutics.
  • Autoimmune Assays and Drug Discovery Services Human-relevant in vitro autoimmune assays including mixed lymphocyte reactions, T cell activation/suppression/polarisation assays, Treg suppression assays, macrophage polarisation assays, B cell depletion assays, and T cell depletion assays for immunotherapy evaluation.
  • RoukenCells Cell Product Line Cell product arm of RoukenBio providing off-the-shelf engineered cell lines including IndEx-2 cell lines, reporter cell lines, and standardised/bespoke primary human immune cell banks for seamless integration into customers' internal assay workflows.

Quantifiable outcome

  • Net Promoter Score of 79, indicating exceptionally high customer satisfaction and loyalty
  • +2 more outcomes

Companies that use Roukenbio

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Roukenbio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Roukenbio partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • AVS BiocoreStrategic or Co-development Partner · 17 February 2026Strategic partnership to integrate antibody discovery and development services with mechanism-driven functional characterisation. Combines AVS Bio's design-focused discovery platforms with RoukenBio's cell-based and primary immune cell assay systems. Creates an end-to-end antibody engine to improve lead candidate prioritisation and reduce translational uncertainty before IND-enabling studies. AVS Bio has supported over 100 life sciences companies since 2018, with 10 antibodies entering clinical trials.
  • HistologiXminorStrategic or Co-development PartnerGLP & GCP compliant CRO specialising in advanced tissue-based biomarker analysis including histology, immunohistochemistry (IHC), immunofluorescence (IF), in situ hybridisation (ISH), and digital image analysis services for therapeutic and medical device development.
  • ScendeaminorStrategic or Co-development PartnerLeading product development and regulatory consulting practice serving pharmaceutical and biotechnology industry. Offers strategic and operational support in quality/CMC, non-clinical/toxicology, clinical/medical and regulatory affairs. Team members based in UK, Ireland, Netherlands and US.
  • EvitriaminorStrategic or Co-development PartnerEstablished global antibody expression service provider located in Zurich, Switzerland. Specialised in CHO-based transient expression of antibodies including bispecific and fusion antibodies. Track record of more than 125,000 transfections performed and more than 20,000 antibodies expressed and purified.
  • ScreenIn3DminorStrategic or Co-development PartnerDeveloper of best-in-class lab-on-chip screening platforms for 3D disease models. Offers patented technology providing higher throughput investigation of candidate molecules on translational live tissue samples and complex 3D models. Delivers over 20 times more data than existing methods.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Roukenbio competitors and assessment

Company assessment

Broad incumbents

  • Inotiv: Discovery and preclinical CRO providing immunology, cell-based assay and biosimilar services; competes in adjacent preclinical spaces with mid-tier scale similar to RoukenBio.
  • Eurofins Discovery: Large global CRO network with immunology and cell-based assay capabilities as part of a broad discovery services portfolio; competes with RoukenBio on immunology projects but as one of many service lines.
  • Labcorp Drug Development (Fortrea): Large CRO offering immunology, cell-based assay and biosimilar characterization services across the full drug development lifecycle - significant overlap with RoukenBio's preclinical offerings, especially in biosimilars.
  • Pharmaron: Global CRO/CDMO with cell biology, immunology and biosimilar capabilities; competes with RoukenBio on preclinical immunology projects, with broader integrated discovery-to-manufacturing offering.
  • Charles River Laboratories: Major global CRO offering immunology, cell-based assays and biosimilar services as part of an end-to-end discovery and development portfolio - broader scope and scale but overlapping capabilities.

Emerging players

  • iQ Biosciences: Smaller specialty CRO offering primary immune cell isolation, cell-based assays and immunology services to biopharma - emerging niche player with similar but more limited offering than RoukenBio.

Direct peers

  • ProImmune: Specialty immunology services CRO offering cell-based assays, MHC-peptide binding, and immune monitoring services to biopharma - directly comparable niche specialization and customer base to RoukenBio.
  • Caprion Biosciences (CellCarta): Immunology and biomarker CRO with strong flow cytometry, immunophenotyping and cell-based assay capabilities serving biopharma; operates at a slightly larger scale but with similar specialty positioning.
  • ReachBio Research Labs: Specialty CRO focused on hematology and immunology cell-based assays, including primary human cell assays - direct niche competitor in similar cell-based immunology services.
  • ImmunXperts: Immunology-focused CRO specializing in immune cell assays, antibody characterization and immunogenicity testing using primary human immune cells - closely overlaps RoukenBio's core preclinical immunology service offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights1 record

Customer concentration

Roukenbio social profiles

Digital presence

Roukenbio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Roukenbio leadership team

Management profile

Number of profiles

Profiles4 records

Roukenbio subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Roukenbio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Roukenbio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roukenbio

What does Roukenbio do?

RoukenBio is a preclinical immunology Contract Research Organisation (CRO) providing bespoke drug discovery and development services from early discovery through pre-IND testing. Its core offering covers immune cell-based assays, custom cell line engineering, biosimilar characterisation, immunotoxicology, and therapeutic area expertise in allergy and autoimmunity, supported by proprietary IndEx-2 and LocIn platforms. The RoukenCells sub-brand additionally supplies off-the-shelf engineered cell lines, reporter cells, and immune cell banks for client in-house workflows.

Is Roukenbio a public or private company?

Roukenbio is a private company. It is classified as private equity controlled and is currently operating.

When was Roukenbio founded?

Roukenbio was founded in 2015. It employs 101 to 250 people.

Where is Roukenbio based?

Roukenbio is headquartered in Motherwell, United Kingdom, in the Europe region.

How does Roukenbio make money?

One revenue line is on record: contract Research Services.

Who are Roukenbio's main competitors?

Broad incumbents on record are Inotiv, Eurofins Discovery, Labcorp Drug Development (Fortrea), Pharmaron and Charles River Laboratories. iQ Biosciences is listed as an emerging player. Direct peers are ProImmune, Caprion Biosciences (CellCarta), ReachBio Research Labs and ImmunXperts.

Does Roukenbio have an API?

No public API is recorded for Roukenbio.

What industry is Roukenbio in?

Roukenbio's product category is Preclinical Immunology Contract Research Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ContractpharmaRoukenBio, AVS Bio Form Antibody‑Development PartnershipRoukenBio and AVS Bio have formed a strategic partnership to streamline therapeutic antibody development by combining discovery, optimization, and functional testing within a single workflow. The collaboration aims to improve early mechanistic insights, enhance lead selection, and reduce late-stage failures while supporting data-driven decision-making.FierceBiotechImmunology CRO RoukenBio pens pact with AVS Bio for more predictable antibody developmentPreclinical CRO RoukenBio has entered into a partnership with Connecticut-based biologics discovery specialist AVS Bio to improve the predictability of therapeutic antibody development. The collaboration will combine AVS Bio's antibody discovery and computational expertise with RoukenBio's immunology assay platforms, integrating high-quality antibody discovery with early mechanism-driven functional characterization to help avoid late-stage trial failures. The partnership incorporates a data-driven approach intended to improve R&D decision-making across the drug development process.PharmiWeb.comRoukenBio and AVS Bio Announce Strategic Partnership to Integrate Design-Focused Antibody Discovery and Optimisation with Mechanism-Driven Functional CharacterisationRoukenBio and AVS Bio announced a strategic partnership on February 17, 2026, in Motherwell, Scotland, to integrate antibody discovery and development services with mechanism-driven functional characterisation for biotherapeutic developers. The collaboration creates an end-to-end antibody engine combining AVS Bio's design-focused discovery platforms with RoukenBio's cell-based and primary immune cell assay systems, aiming to improve lead candidate prioritisation and reduce translational uncertainty before IND-enabling studies. The companies stated the partnership reflects a shared philosophy that successful antibody therapeutics require both high-quality discovery and early, mechanism-driven validation in physiologically relevant biological systems.AntibodyanalyticsPreclinical Contract Research Organisation for ImmunologyRoukenBio is promoting its services as a preclinical contract research organization specializing in immunology and drug discovery. The company highlights its capabilities in supporting the development of small molecules, large molecules, and advanced therapeutics from early discovery through to clinical phases. It emphasizes the use of state-of-the-art assay platforms and custom development capabilities to deliver precise scientific data for global customers.